Novo Nordisk gains after boosting 2023 outlook on Ozempic, Wegovy sales surge
) gained 2% in pre-open trading Friday after raising its sales and earnings outlook for the year amid robust growth of weight loss drugs Ozempic and Wegovy.
The company now sees 2023 sales growth of 32-38%, versus its prior outlook of 27-33%. They see operating profit growth of 40-46%, versus its prior outlook of 31-37%. Novo said the updated sale outlook is"... primarily reflecting higher full-year expectations for Ozempic® volumes sold in the US and gross-to-net sales adjustments for Ozempic® and Wegovy® in the US."Comment Guidelines
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
{username} Just Now Share Follow this postUnfollow this post Save Saved. See Saved Items . This comment has already been saved in your Saved Items Author's response{commentContent} Reply 00 Report {username} Just NowAuthor's response Share Follow this postUnfollow this post Save Saved. See Saved Items .
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk warns online offers of fake Ozempic, Wegovy are risingNovo Nordisk (NOVOb.CO) warned on Thursday of a surge in counterfeit versions of its weight-loss drug Wegovy and diabetes drug Ozempic offered online, as German authorities gave more details of complex European trades in a fake drug case.
Read more »
Novo Nordisk: Online Ozempic, Wegovy Fakes RisingNovo Nordisk warned on Thursday of a surge in counterfeit versions of its weight-loss drug Wegovy and diabetes drug Ozempic offered online, as German authorities gave more details of complex European trades in a fake drug case.'Novo Nordisk has seen a significant increase...
Read more »
Dutch Blockchain Week 2023 | November 13-17, 2023The Blockchain Netherlands Foundation (BCNL) is excited to announce the fifth edition of Dutch Blockchain Week (DBW). Scheduled to take place from November 13th to 17th, this year's event builds upon the success of last year, promising more ecosystem events, more partners and more opportunities to explore everything about blockchain.
Read more »
Stocks making the biggest moves midday: Novo Nordisk, DaVita, Exxon, Amgen and moreThese are some of the stocks posting the largest moves midday.
Read more »
Stocks making the biggest moves midday: Novo Nordisk, DaVita, Exxon Mobil, Amgen and moreThese are some of the stocks posting the largest moves midday.
Read more »
DaVita plays down Ozempic’s potential in treating kidney diseaseDialysis company’s stock falls again after Novo Nordisk said Ozempic was successful in treating kidney failure in a trial
Read more »